Ullswater Investments · EU Funding Calls
All calls › Horizon Europe › HORIZON-MISS-2027-02-CANCER-02
ForthcomingHorizon Europe

Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients afflicted by lung, bowel, breast or prostate cancer [1] , will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer…

Deadline 16 Sep 2027Opens 10 Feb 2027Budget €20MIndicative grants 3EU contribution per project €7M–€10MSingle stageHORIZON Innovation Actions

Funding and competition

  • 3grants expected (official)
  • €7M–€10MEU contribution per project
  • €6Mmedian EU grant of the most similar funded projects
  • 67projects funded in earlier topics of this programme line

Success rates vary widely between topics (often from below 5% to above 30%). Ask us for the success-rate history of this topic before you commit to a proposal.

Organisations with a track record in this topic

Organisations that took part in the EU-funded projects most similar to this call (Horizon Europe and Horizon 2020), ranked by how close those projects are to the call, how recent they are and whether the organisation coordinated them. Being listed does not mean an organisation is looking for partners: use the list to target your outreach.

OrganisationCountryTypeSimilar EU projectsAs coordinatorExamples (CORDIS)
Oslo Universitetssykehus Hf
Oslo
NorwayUniversity102EU-CIP, PRIME-ROSE, ENACT-65
Erasmus Universitair Medisch Centrum Rotterdam
Rotterdam
NetherlandsUniversity105EOSC4Cancer, EU-TOPIA, Mac4Me
Deutsches Krebsforschungszentrum Heidelberg
Heidelberg
GermanyResearch organisation81EU-CIP, 4.UNCAN.eu, EUonQoL
European Cancer Organisation
Bruxelles / Brussel
BelgiumOther80EU-CIP, EUonQoL, CANDLE
Karolinska Institutet
Stockholm
SwedenUniversity100PRIME-ROSE, EOSC4Cancer, ECHoS
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam
NetherlandsResearch organisation90PRIME-ROSE, 4.UNCAN.eu, ENACT-65
Biobanks And Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric)
Graz
AustriaResearch organisation71EU-CIP, EOSC4Cancer, CANDLE
Region Hovedstaden
Hillerod
DenmarkPublic body90PRIME-ROSE, EUonQoL, UNCAN-Connect
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio)
Barcelona
SpainResearch organisation61EU-CIP, PRIME-ROSE, 4.UNCAN.eu
Hus-Yhtyma
Helsinki
FinlandResearch organisation71PRIME-ROSE, CANDLE, ECHoS
Charite - Universitaetsmedizin Berlin
Berlin
GermanyUniversity61EU-CIP, CANDLE, Sagittarius
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer
Barcelona
SpainResearch organisation71DEFINITIVE, EOSC4Cancer, IMPORTANT
Tartu Ulikool
Tartu
EstoniaUniversity614.UNCAN.eu, ECHoS, UNCAN-Connect
Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer Aisbl
Bruxelles / Brussel
BelgiumResearch organisation53DE-ESCALATE, EUonQoL, LEGATO
Istituto Europeo Di Oncologia Srl
Milano
ItalyCompany70PRIME-ROSE, DEFINITIVE, EUonQoL

Spanish organisations with experience in this field

The Spanish organisations that appear most often in the closest funded projects.

What a typical winning consortium looks like

  • 21partners (median)
  • 11countries (median)
  • 11%of partners are SMEs
Research organisation 38%University 22%Other 14%Public body 14%Company 12%

Based on the 25 funded projects closest to this call. Use it as a benchmark, not a rule: always check the call conditions for the minimum consortium.

Most similar funded projects

Read their CORDIS pages to see the full consortium, results and deliverables.

  • EU-CIP – EUropean Cancer Information Portal (HORIZON · 2025 · HORIZON-MISS-2024-CANCER-01-06)
  • DE-ESCALATE – Intermittent androgen deprivation therapy in the era of androgen receptor pathway inhibitors; a phase 3 pragmatic randomised trial (HORIZON · 2023 · HORIZON-MISS-2022-CANCER-01-03)
  • PRIME-ROSE – PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials (HORIZON · 2023 · HORIZON-MISS-2022-CANCER-01-03)
  • 4.UNCAN.eu – A Coordination and Support Action to prepare UNCAN.eu platform (HORIZON · 2022 · HORIZON-MISS-2021-UNCAN-01-01)
  • DEFINITIVE – Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer (HORIZON · 2023 · HORIZON-MISS-2023-CANCER-01-03)
  • ENACT-65 – ENabling ACTion on Integrated Nutritional and Exercise Care in Cancer – for Patients 65 and Beyond (HORIZON · 2026 · HORIZON-MISS-2025-02-CANCER-05)

Live partner requests

Organisations actively looking for partners publish their requests on these official platforms.

Partner search on this topic

On the official topic page, open “Partner search announcements” to see organisations that have declared interest in this exact topic, or publish your own (EU Login required).

Open the topic ↗

Health NCP Net

Network of Health National Contact Points: partner search, brokerage events and proposal support for Cluster 1 Health and IHI.

Open ↗

EU Funding & Tenders Partner Search

Search all organisations registered in the portal by keyword, programme, country and organisation type.

Search organisations ↗

Enterprise Europe Network

Europe's largest database of business, technology and R&D cooperation requests. Filter by “Research and development request”.

Browse requests ↗

Upcoming info days and brokerage events

Brokerage events are where most consortia are built.

All EU funding events →

Building a consortium for this call?

Publish what you are looking for or what you can offer on the Ullswater partner board. We review each request, publish it on this page and introduce you to suitable partners.

Post a partner request

Track-record data: CORDIS open data (European Commission), organisation level only, refreshed weekly. Rankings are calculated automatically by Ullswater Investments from text similarity between the call and funded projects; they are indicative.